Neuroone Medical Technologies is trading 5.6% higher at $1.04, with no company-specific catalyst identified for the October 2 move.
- Recent company news does not establish a direct catalyst for the gain.
- The broader market is higher after September payrolls came in at 29,000, below expectations, prompting Treasury yields to fall and reducing expectations for a rate increase. This risk-on backdrop may be supporting the stock, though the link is unconfirmed.